Marketing-authorisation holder
Biocryst
3 medicines in 1 country, as authorisation holder.
Loading…
Marketing-authorisation holder
3 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ORLADEYO110mg base | 150mg base · Capsule | Berotralstat | United States | Marketed | 2020 |
| ORLADEYO108mg base/packet | 132mg base/packet | 72mg base/packet | 96mg base/packet · Pellets | Berotralstat | United States | Marketed | 2025 |
| RAPIVAB200mg/20ml (10mg/ml) · Solution | Peramivir | United States | Marketed | 2014 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 3 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Keep Biocryst’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a call